A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae
ConditionCOVID-19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this study is to understand why some people experience long term effects, such as shortness of breath and fatigue, after a severe COVID-19 infection
Eligibility criteria
Qualifiers
Age ≥18 years at screening, PCR confirmed COVID19 illness (+PCR defines day 0 of illness), hospitalization for COVID-19, absence of pre-existing history of interstitial lung disease, or significant other lung disease.
Severity of illness will be categorized as moderate disease (supplemental oxygen need 1-8L at any time during hospitalization), severe disease (need for high flow oxygen delivery ≥8L at any time during hospitalization) and critical illness (need for ICU admission or mechanical ventilation).
Age ≥18 years at screening
PCR confirmed COVID-19 cases who had nonsymptomatic or mild acute infection that do not require hospitalization 7,48,49
Disqualifiers
Inability to provide informed consent, evidence of pre-existing interstitial lung disease or chronic lung disease;
Active cigarette smoking, vaping or other inhalation use.
Immunocompromised host status due to ongoing therapy with methotrexate, CellCept, azathioprine, rituximab, cyclophosphamide or other biologic agents;
> 20 pack year smoking history.
Trial design
Treatments tested in this trial
- Bronchoscopies and Bronchoalveolar Lavages (BALs)
- Chest Tomography (CT)
- Electrocardiogram (ECG)
- Pulmonary function tests (PFTs)
- 6 minute walk test (6MWT)
Treatment groups
67 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov